左心室射血分数保留的心力衰竭患者心率震荡的临床意义研究

目的研究左心室射血分数保留的心力衰竭(heart failure with preserved ejection fraction,HFPEF)患者窦性心率震荡(heart rate turbulence,HRT)的变化以及临床意义。方法选择52例在河南科技大学第一附属医院接受治疗的HFPEF患者作为HEPEF组,另选择无心肌缺血及器质性心脏病变患者30例作为对照组。行24h动态心电图检查,计算HRT指标:震荡初始值(turbulence onset,TO)和震荡斜率(turbulence slope,TS)。行超声心动图检查测定评价心功能不全的相关指标,比较HFPEF组与对照组之间HRT的差异。结果与对照组比较,HFPEF组TO明显升高[(0.17±1.40)%vs(-0.26±0.99)%,P=0.027],TS明显降低[(0.88±2.51)ms/RRI vs(2.60±2.76)ms/RRI,P=0.003]。Pearson相关性分析显示左心室舒张末期容积指数与TO负相关(r=-0.55,P=0.01),与TS呈正相关(r=0.23,P=0.03);舒张早期二尖血流速度和二尖瓣环运动速度比值与TO正相关(r=0.21,P=0.04),与TS呈负相关(r=-0.39,P=0.01)。结论 HFPEF患者窦性心率震荡现象明显受损,提示心脏自主神经调节功能下降,并且反映左心室舒张功能。     

比索洛尔联合坎地沙坦对心力衰竭患者血浆脑利钠肽的影响

目的探讨比索洛尔联合坎地沙坦对慢性心力衰竭（CHF）患者血浆脑利钠肽（BNP）浓度的影响。方法将200例CHF患者随机分为治疗组和对照组,对照组给予常规治疗,治疗组在常规治疗基础上加用比索洛尔和坎地沙坦,疗程为6个月。测定两组患者用药前及给药6月后血浆BNP浓度、心脏射血分数（EF）、左室短轴缩短率（FS）及心脏指数（CI）。结果治疗组显效率、有效率、无效率分别为51％、40％、9％,对照组分别为40％、31％、29％,两组比较差异有统计学意义（P〈0．01）。治疗后治疗组EF、FS、CI改善（P均〈0．01）,血浆BNP浓度降低（P〈0．01）。结论比索洛尔联合坎地沙坦可降低CHF患者的血浆BNP浓度,改善心功能。     

脑钠肽与左室射血分数评估左心功能的常见误差分析

目的观察血浆脑钠肽(BNP)水平与左室射血分数(LVEF)对左心功能的评估效果,分析常见误差的原因。方法收集不同心功能水平患者320例,分别按BNP及LVEF分组,采用Biosite公司脑钠素试剂盒和Tri-age BNP测试仪进行BNP检测。结果以BNP(ng/L)分组,各组BNP水平比较,差异均有统计学意义(P<0.05);BNP≥100ng/L组与其他组LVEF值比较,差异有统计学意义(P<0.05)。以LVEF(%)分组,各组间BNP水平、LVEF、左室内径(LVEDd)比较,差异均有统计学意义(P<0.05);其中LVEF≥50%者270例,其中BNP<400ng/L者247例(91.5%)。结论随血浆BNP水平逐渐增高,LVEF均值逐渐降低,总体呈反比趋势;亦有心肌收缩力明显降低,而BNP升高不明显的情况。临床医生对各种检测指标应综合分析,不能过度依赖某一项检测。     

比索洛尔治疗慢性心力衰竭患者的疗效观察

目的:探讨比索洛尔治疗慢性心力衰竭患者的疗效。方法:104例慢性心力衰竭患者被随机分成两组:对照组52例,予以常规用药(强心、利尿、扩血管)+咪哒普利治疗;治疗组52例,在常规用药+咪哒普利基础上加用比索洛尔治疗,疗程12～16周,观察治疗前后心功能、左室射血分数(LVEF)、左室舒张末内径(LVEDd)、左室收缩末内径(LVESd)、心率及血压等指标的变化。结果:治疗组总有效率明显高于对照组(92.31%:73.08%,P0.05);治疗组治疗后LVESd较治疗前显著降低[(49.86±5.20)mm:(61.80±4.58)mm,P0.05],且较对照组(57.65±4.20)mm降低更显著,P0.05,两组治疗后LVEF均有明显增高(P0.05～0.01),且治疗组明显高于对照组[(48.84±4.45)%:(37.58±3.15)%,P0.05],治疗组收缩压、舒张压、心率均较治疗前明显改善(P0.05～0.01),且舒张压[(69.4±12.98)mmHg:(75.97±13.62)mmHg]、心率[(70.99±10.7)次/min:(75.73±9.4)次/min]较对照组明显降低(P均0.05)。结论:在常规用药+咪哒普利基础上加用比索洛尔治疗慢性心力衰竭患者疗效更显著。     

重组人脑利钠肽治疗难治性心力衰竭的临床研究

目的研究重组人脑利钠肽(rhBNP)治疗难治性心力衰竭(RHF)的临床疗效。方法选择心功能分级(NYHA)Ⅲ～Ⅳ级的RHF患者60例,分为rhBNP组(rhBNP治疗)和对照组(硝普钠治疗)各30例,观察两组患者治疗前后生命体征、相关心功能指标和氨基末端脑钠肽前体(NT-proBNP)浓度的变化。所有患者均知情同意。结果 (1)与治疗前比较,rhBNP组治疗后左心室射血分数(LVEF)升高(38.5%±7.3%比28.4%±6.0%),24 h尿量增多[(920.0±320.0)ml比(500.0±120.0)ml],心率[(91.0±6.5)次/min比(112.0±1.3)次/min]、血肌酐[(86.0±17.2)μmol/L比(101.6±18.5)μmol/L]下降,差异均有统计学意义(均为P<0.05);(2)两组治疗后,rh-BNP组LVEF高于对照组(31.7%±8.9%),24 h尿量多于对照组[(740.0±140.0)ml],心率低于对照组[(107.0±7.7)次/min],肌酐低于对照组[(101.4±15.6)μmol/L],差异均有统计学意义(均为P<0.05);(3)两组治疗前后,NT-proBNP、收缩压(SBP)和左心室舒张末期内径(LVDd)差异均无统计学意义(P>0.05)。结论 rhBNP可明显改善RHF患者的心功能,其近期效果优于硝普钠治疗。     

射血分数正常的老年男性患者营养不良参数与血清氨基末端B型利钠肽前体水平升高的关系

目的 探讨射血分数正常的高龄老年男性患者营养不良参数与血清氨基末端B型利钠肽前体(NT-proBNP)水平的相关性. 方法 入选2005年1月至2010年12月在解放军总医院就医的老年男性住院患者197例,年龄80～95岁,平均(85.4±9.7)岁.超声心动图采用胸骨旁左心室长轴切面测量并计算左心室射血分数.采用电化学发光免疫法测定血清NT-pro-BNP水平. 结果 营养不良患者较营养正常患者血清NT-proBNP增加,(1375.2±1891.7)ng/L比(711.9±1063.3)ng/L(P=0.006).Pearson相关性分析结果显示,血红蛋白、血清白蛋白、血清前白蛋白和体质指数与血清NT-proBNP水平呈负相关(均P＜0.05).多变量Logistic回归分析结果显示,仅血清前白蛋白(P=0.028)和体质指数(P=0.006)与血清NT-proBNP水平升高相关.受试者工作特征(ROC)曲线分析结果显示,营养不良参数能够预测血清NT-proBNP水平升高,体质指数ROC曲线下面积0.7(P=0.002),预测敏感性为75.5％、特异性为54.4％;血红蛋白曲线下面积0.7(P=0.004),预测敏感性为51.0％、特异性为70.2％;白蛋白曲线下面积0.6(P-0.036),预测敏感性为38.8％、特异性为84.2％;前白蛋白曲线下面积0.6(P-0.002),预测敏感性为89.8％、特异性为31.6％. 结论 射血分数正常的老年男性营养不良参数体质指数、血红蛋白、白蛋白和前白蛋白能用于预测血清NT proBNP水平的升高;体质指数、前白蛋白是血清NT proBNP水平升高的独立影响因素.     

急性冠状动脉综合征患者脑利钠肽水平与左心室射血分数的相关性研究

目的观察急性冠状动脉综合征(ACS)患者临床特点,探讨血浆B型利钠肽(BNP)水平与左心室射血分数(LVEF)的关系。方法选取连续入院的124例ACS患者,记录其各项危险因素,测定血浆BNP水平和LVEF,分析男性(87例)与女性(37例)患者之间、ST段抬高型ACS患者(72例)与非ST段抬高型ACS患者(52例)之间以上指标的特点;探讨BNP水平与LVEF的相关性。结果 (1)与非ST段抬高型ACS组比较,ST段抬高型ACS组中有明确高血压病史者比例较高[69.4%(50/72)比46.1%(24/52)],BNP水平较高[(314.77±69.63)ng/L比(117.20±22.73)ng/L],而LVEF较低[(54.72%±11.71%)比(64.07%±11.18%)],差异均具有统计学意义(均为P<0.05);两组患者的性别构成比(男/女:33/19比54/18)、平均年龄[(63.1±9.5)岁比(66.0±11.7)岁]、糖尿病病史[16例(30.8%)比20例(27.8%)]、血脂异常病史[4例(7.7%)比13例(18.1%)]及吸烟史[30例(57.7%)比46例(63.9%)]差异均无统计学意义(均为P>0.05);(2)女性患者患病年龄晚于男性[(69.9±8.4)岁比(62.6±11.1)岁],具有高血压病史者女性多于男性[73.0%(27/37)比54.0%(47/87)],有吸烟史者女性少于男性[16.2%(6/37)比80.5%(70/87)],BNP水平女性高于男性[(402.84±89.22)ng/L比(159.22±30.57)ng/L],LVEF则女性低于男性[(57.07%±12.67%)比(62.35%±10.82%)],差异均具有统计学意义(均为P<0.05);两组间糖尿病患者比例[25.3%(22/87)比37.8%(14/37)]、高脂血症患者比例[17.2%(15/87)比5.4%(2/37)]及非ST段抬高型ACS患者比例[37.9%(33/87)比51.4%(19/37)],差异均无统计学意义(均为P>0.05);(3)ACS患者BNP与LVEF呈负相关(r=-0.349,P<0.05)。结论 ST段抬高型ACS患者较非ST段抬高型ACS患者高血压患病率高、BNP水平高而LVEF低;女性较男性ACS患者高血压患病率高,BNP水平高而LVEF低。BNP可作为早期评估ACS患者心功能水平的指标。     

射血分数正常心力衰竭患者241例临床分析

目的：对比分析心力衰竭（HF）患者中左心室射血分数正常者（HFNEF）与射血分数降低（SHF）患者的临床和心脏结构的特点。方法：选择我院心内科连续收治,符合研究条件者共241例,其中HFNEF88例,SHF153例,分析其病因、心脏结构特点和HF危险因素。结果：与SHF患者相比,HFNEF患者的年龄较大[（75．43±10．43）岁比（80．25±7．74）岁],女性患者较多（占78．4％）,P均〈0．001。HFNEF患者的直接病因以高血压病（33．0％）、冠心病（25．0％）最多见,SHF患者的最常见病因为冠心病,尤其是陈旧性心肌梗死患者。HF—NEF患者中心房颤动的患病率较高,左心室肥厚多见（P均〈0．001）,但左心室重构的程度较轻;SHF患者血清N末端脑钠肽前体水平显著降低（P〈0．001）,肌酐水平亦降低（P〈0．05）。结论：心力衰竭左心室射血分数正常患者多为老年女性,主要病因中以高血压和冠心病最多,左室肥厚和房颤的患病率高。     

左心室射血分数保留的心力衰竭研究进展

<正>心力衰竭(心衰)是由于任何心脏结构或功能异常导致心室充盈或射血能力受损的一组复杂临床综合征,其主要临床表现为呼吸困难和乏力(活动耐量受限)以及液体潴留(肺淤血和外周水肿)。1定义及诊断标准在美国心脏病学学院基金会(American College of Cardiology Foundation,ACCF)和AHA联合发布的2013年心     

左心室射血分数与认知损害的关系

目的分析LVEF与认知损害的关系,明确慢性心功能不全是否为认知损害的危险因素。方法选择本院进行超声心动图检查的患者250例,超声心动图检测LVEF,患者根据LVEF分为4组:LVEF≤60%组53例、61%~65%组62例、66%~70%组75例、≥71%组60例。应用简易智能状态检查量表(MMSE)评估认知功能,又分为认知损害组50例和认知正常组200例。单因素及多因素分析LVEF与认知损害的关系。结果LVEF≤60%组,61%~65%组,66%~70%组和≥71%组认知损害患病率存在显著差异(45.3%vs 24.2%vs 12.0%vs3.3%,P=0.000);线性趋势相关检验显示,认知损害患病率与LVEF存在显著线性关系(χ2=33.630,P<0.01)。MMSE得分与LVEF呈正相关(r=0.372,P<0.01)。与认知损害相关的因素有高血压(OR=13.649,95%CI:3.379~55.132,P=0.000);受教育年限(OR=0.855,95%CI:0.786~0.930,P=0.000)以及LVEF(OR=0.929,95%CI:0.899~0.959,P=0.000)。结论 LVEF降低是认知损害的独立危险因素。     

B型钠尿肽与慢性心力衰竭患者临床预后的关系研究

目的探讨B型钠尿肽(BNP)对慢性心力衰竭(CHF)患者的临床诊断价值、心功能评价及危险分层的意义。方法入选CHF患者208例,参照美国纽约心功能分级,心功能Ⅰ级50例(1组);心功能Ⅱ级51例(2组);心功能Ⅲ级55例(3组);心功能Ⅳ级52例(4组)。血浆BNP水平测定用放射免疫法;LVEF用彩色多普勒超声心动诊断仪测定。结果 1～4组患者血浆BNP水平分别为(78.05±1 2.86)ng/L、(235.38±36.65)ng/L、(587.98±75.78)ng/L、(1203.87±189.96)ng/L,与1组比较,2、3、4组患者BNP水平随着心功能级别的递增而显著增加,差异有统计学意义(P<0.01);2、3、4组患者随着BNP水平的升高,LVEF、6 min步行距离逐渐下降,随着CHF程度的加重,年住院次数增加;随访2、3、4组患者5年病死率分别为0,18.18%,44.23%;5年死亡风险随BNP水平的升高或治疗后下降幅度不明显而增大(P<0.01);BNP对LVEF<50%的CHF患者诊断敏感性、特异性分别为82.35%、75.42%;ROC曲线下面积为0.90。结论血浆BNP对CHF患者有较好的临床诊断价值,是CHF患者死亡风险较准确的评价指标之一;CHF患者血浆BNP水平与LVEF、6 min步行距离呈负相关。     

Prognostic role of B-type natriuretic peptide in patients with diabetes and acute decompensated heart failure.

BACKGROUND: Several studies have reported the prognostic value of natriuretic peptides, but their predictive value in patients with diabetes mellitus is unknown. The aim of the study was to test the hypothesis that measurement of brain natriuretic peptide (BNP) levels in ambulatory patients with congestive heart failure (CHF) and diabetes can predict the occurrence of cardiovascular events at 6-month follow-up. METHODS: We enrolled 145 consecutive patient with diabetes [age 72 +/- 9 years, hypertension (21%), ischaemic heart disease (52%), atrial fibrillation (22%), preserved left ventricular function (29%)] seen in the outpatient heart failure clinic after an acute episode of cardiac failure. RESULTS: The median (25th/75th interquartile range) BNP concentrations at discharge were 186 (75-348) pg/ml. At 6-month clinical follow-up 10/145 (7%) subjects had died and 31/145 (21%) had been readmitted because of cardiac decompensation. BNP values of 200 and 500 pg/ml were found to have the best compromise between sensitivity (88 and 46%, respectively) and specificity (71 and 89%, respectively) for predicting events at 6 months. Multivariate Cox regression analysis identified only two parameters as predictors of events: serum creatinine [hazard ratio (HR) = 3.3; P = 0.02], and BNP plasma level BNP cut-off values (HR = 3.8; P = 0.03 for 201-499 pg/ml and HR = 7.7; P = 0.001 for > or = 500 pg/ml). CONCLUSION: These results suggest that BNP and serum creatinine are strong predictors of clinical events in patients with diabetes and CHF. In these patients, clinical outcome might be stratified by plasma BNP levels.     

小剂量倍他乐克治疗充血性心力衰竭对血浆脑钠尿肽水平的影响

目的观察小剂量倍他乐克治疗充血性心力衰竭（CHF）后,患者血浆脑钠尿肽（BNP）水平的改变。方法选择心功能Ⅲ～Ⅳ级心衰患者31例,在常规抗心衰基础上加用小剂量倍他乐克,观察治疗前后血浆BNP水平的变化。结果心率明显减慢,心胸比和血压均较治疗前降低,左室舒张末期内径（LVDd）缩短,左室射血分数（LVEF）则较治疗前提高,BNP值显著降低,总有效率达81%。结论小剂量倍他乐克治疗CHF可使BNP值显著下降,动态监测患者血浆BNP水平有助于了解CHF治疗效果及预后。     

慢性重度心力衰竭患者血B型利钠肽浓度正常的临床意义探讨

目的 探讨慢性重度心力衰竭(心衰)患者出现血B型利钠肽(B-type natriuretic peptide,BNP)浓度正常的临床意义.方法 采用前瞻性对照研究的方法观察心功能Ⅲ～Ⅳ级的慢性重度心衰患者57例.血BNP浓度正常的13例患者为研究组(A组),血BNP浓度明显升高的44例为对照组(B组),分析两组患者的临床特点,判定血BNP浓度正常对于慢性重度心衰患者的意义.结果 两组患者的基线情况差异无统计学意义.A组的左室舒张末期内径大于B组[(70.56±4.33)mm与(63.73±3.75)mm,P＜0.05];A组的左室射血分数小于B组[(24.16±2.50)%与(28.49±2.63)%,P＜0.05].A组中能耐受美托洛尔的人数比例少于B组[(7/13)与(39/44),P＜0.05],耐受剂量低于B组[(12.5±6.25)mg/d与(24.20±11.22)mg/d,P＜0.05].两组血BNP浓度在稳定期各时间段无明显改变,但在慢性心衰急性发作与缓解后,A组无显著性改变[(74.03±11.18)ng/L与(71.38±11.68)ng/L,P＞0.05],而B组改变明显[(962.73±165.00)ng/L与(876.24±167.70)ng/L,P＜0.05].随访中,A组病死率高于B组(11/13与6/44,P＜0.05).Logistic多因素回归分析显示:血BNP降低为预测重度慢性心衰患者心原性死亡的独立危险因素(OR值45.488,95%可信区间5.322～388.791),P＜0.05.结论 慢性重度心衰患者出现血BNP浓度正常提示BNP分泌机制的耗竭和心脏功能的进一步恶化.     

慢性心力衰竭患者脑钠肽水平与心功能的相关性

目的 探讨血清脑钠肽素（BNP）水平判断慢性心力衰竭患者心功能状态的价值。方法采用ELISA法测定54例慢性心力衰竭患者（心衰组）和30例健康体检者（对照组）血清BNP水平,并对其与左心功能指标左室射血分数（LVEF）、左室短轴缩短率（FS）、左室舒张末内径（LVEDD）的相关性进行分析。结果心衰组血清BNP水平明显高于正常,BNP水平随NYHA分级升高而升高;BNP水平与LVEF及FS呈负相关,与LVEDD呈正相关。结论血清CNP浓度可作为反映心功能状态的指标,亦可作为诊断心衰和判断心衰患者预后的指标。     

利钾尿肽和心房钠尿肽的水平与心功能关系的研究

目的探讨利钾尿肽(KP)和心房钠尿肽(ANP)在慢性心力衰竭(CHF)中的变化及其意义。方法用放射免疫分析方法测定50例CHF患者发病不同时期血浆KP和ANP含量。结果CHF患者在发病第1天血浆KP、ANP水平最高,随着病情的好转而逐渐降低,不同的心功能分级之间有显著差异,而与左心室射血分数呈显著负相关。结论血浆KP含量的改变在CHF病理生理中起着一定的作用,并与心功能程度密切相关。     

Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure

BACKGROUND: Congestive heart failure (CHF) is characterized by neurohormonal activation, including increased plasma concentrations of atrial natriuretic peptide (ANP) and N-terminal ANP (N-ANP). Onset of atrial fibrillation (AF) further increases these peptides, but it may be hypothesized that concentrations decrease during longstanding AF due to inherent atrial degeneration. AIM: We sought to investigate the relation between neurohormonal activation in patients with CHF and the duration of concomitant AF. METHODS: The study group comprised 60 patients (age 70 +/- 8 years) with advanced CHF due to left ventricular systolic dysfunction (left ventricular ejection fraction (LVEF) < 0.35) and chronic AF (duration 21 (1-340) months). Plasma neurohormone concentrations were measured, and multiple regression analysis was performed to identify their clinical predictors. RESULTS: Median plasma neurohormone concentrations were: ANP 113 pmol/l, N-ANP 1187 pmol/l, norepinephrine 496 pg/ml, renin 127 micro units/l, aldosterone 128 pg/ml and endothelin 8.1 pg/ml. Norepinephrine, renin, aldosterone and endothelin were not significantly related to the duration of AF. In contrast, ANP decreased along with the duration of AF (P = 0.03), while the same trend was observed for N-ANP (P = 0.10). However, for these peptides a first order interaction with LVEF was present, which was not observed in the other neurohormones. In patients with LVEF > 0.25 ANP and N-ANP increased along with the duration of AF, whereas in patients with LVEF < or = 0.25 an inverse relation between ANP (P = 0.02) and N-ANP (P = 0.04) and the duration of AF was present, longer-standing AF being associated with lower concentrations. CONCLUSION: In patients with advanced CHF with low LVEF plasma ANP and N-ANP concentrations decrease during longstanding AF. This finding agrees with the concept that longstanding AF leads to impaired ability of the atria to produce these neurohormones due to inherent degenerative changes.     

Augmented response in plasma brain natriuretic peptide to dynamic exercise in patients with left ventricular dysfunction and congestive heart failure

OBJECTIVES: We have previously demonstrated that patients with symptomatic congestive heart failure (CHF), but not with asymptomatic left ventricular dysfunction (LVD), have augmented plasma atrial natriuretic peptide (ANP) response to exercise. Plasma brain natriuretic peptide (BNP) response to exercise is less extensively studied. The aim of this study was to determine whether responses of plasma BNP during exercise normalized for exercise workload are altered in patients with LVD and CHF. SUBJECTS AND METHODS: Twenty-nine patients with LVD, 32 patients with CHF (NYHA classes II-III) and 27 age-matched control subjects were studied. Ventilatory, plasma ANP and BNP responses were assessed during symptom-limited cardiopulmonary exercise testing. Plasma natriuretic peptide levels were measured at rest and immediately after peak exercise. The increment in plasma BNP was divided by the increment in oxygen uptake (VO2) from rest to peak exercise, and this ratio [BNP exercise ratio: (peak BNP - rest BNP)/(peak VO2 - rest VO2)] was compared amongst the three groups. RESULTS: Peak VO2 (Control, LVD and CHF: 28.2 +/- 1.7, 21.1 +/- 1.8, 16.2 +/- 0.6 ml, min(-1) kg(-1), respectively), anaerobic threshold and peak workload became smaller as heart failure worsened. Resting and peak plasma ANP levels were significantly higher only in CHF, whilst resting and peak plasma BNP levels displayed a significant and continuous increase from normal subjects to LVD and CHF. The ANP exercise ratio (1.25 +/- 0.36, 2.61 +/- 0.57, 7.72 +/- 1.65, ANOVA P = 0.0002) was significantly higher only in patients with CHF, whilst the BNP exercise ratio (0.35 +/- 0.10, 2.60 +/- 0.69, 4.98 +/- 0.97, ANOVA P = 0.0001) was significantly higher in patients with LVD and became progressively higher in patients with CHF. CONCLUSIONS: These data showed that the BNP exercise ratio, an exercise plasma BNP response normalized with exercise workload, was augmented in patients with LVD, and became progressively higher in CHF, suggesting that an augmented exercise BNP ratio exists early in the course of developing CHF.     

老年慢性心力衰竭患者血浆脑钠肽水平观察

目的 研究血浆脑钠肽(BNP)在老年慢性心力衰竭(CHF)患者的诊断、治疗和预后评估中的临床作用. 方法 选取2010年1月至2011年3月我科住院206例＞60岁老年CHF患者,按照纽约心脏病学会(NYHA)心功能分级分为4组,采用ELISA法测定患者血液BNP的水平,并测定左心室射血分数(LVEF).在抗心力衰竭治疗2周后或出院时复测上述指标,进行统计学分析. 结果 按NYHA心功能分级的各组患者血浆BNP的水平差异具有统计学意义,心功能越严重,年龄越大,BNP值越高,而LVEF差异仅在Ⅰ、Ⅲ、Ⅳ级心功能间有意义(P＜0.05);经抗心衰治疗后,患者心衰症状缓解,复测BNP值下降而LVEF升高,但仅BNP的变化有统计学意义. 结论 BNP值可作为较可靠的老年CHF的早期预测参考指标,也可作为判断心功能不全严重程度和疗效以及预测预后的指标,而且操作简便,易于重复.     

B型钠尿肽在非ST段抬高急性冠状动脉综合征患者中的应用

目的分析非ST段抬高急性冠状动脉综合征(non-ST elevation acute coronary syndrome,NSTE-ACS)患者B型钠尿肽水平(B-type natriuretic peptide,BNP)的变化与LVEF的相关性,评估BNP在NSTE-ACS患者近期心功能中的预测作用。方法入选NSTE-ACS患者138例,依据入院后治疗方式分为:6 h内PCI组(组1,47例),5～7 d PCI组(组2,50例),药物保守治疗组(组3,41例)。所有患者于入院即刻、发病48 h及7 d时,测定静脉血清BNP,1个月后测LVEF,比较不同时间点BNP的差异,分析BNP水平与1个月后LVEF的关系。结果 3组患者入院即刻和发病48 h时BNP水平差异无统计学意义(P=0.086、0.279);发病7 d时,与组2和组3比较,组1BNP水平显著下降(P=0.006、0.001);组2与组3比较,差异无统计学意义(P=0.052)。发病7 d BNP水平与1个月后LVEF呈显著负相关(r=-0.56,P0.01)。结论在NSTE-ACS患者中,早期介入治疗可以显著降低发病7 d时BNP水平,BNP水平与近期心功能状态呈显著负相关。